Subcutaneous and IV formulations of tocilizumab yielded similar rates of remission in patients with giant cell arteritis-associated aortitis, according to data published in Arthritis Care & Research.

Analysts covering AbbVie have been fine tuning their models, with fair value per share adjusted slightly from US$245.22 to ...

Many of the listed prices are higher than what 92% of the U.S. population now pays because they have insurance, and the site ...